TRANSTHERA-B (02617) released its performance for the year 2025, with a net loss of 2.96 billion yuan, an increase of 7.8% year-on-year.

TRANSTHERA-B (02617) announced its annual performance for the year ending December 31, 2025. Other income and revenue decreased by 48.6% year-on-year to 9.2 million yuan for the 2025 fiscal year. This decrease was mainly due to a reduction of 5 million yuan in bank deposit interest and financial income, and a decrease of 3.7 million yuan in government subsidies. The net loss was 296 million yuan, an increase of 7.8% compared to the previous year, with a basic loss per share of 0.76 yuan. Research and development costs increased by 1% year-on-year to 2.468 billion yuan for the 2025 fiscal year, remaining relatively stable with slight growth. This was mainly due to the company's focus on core product and key technology research and development, optimizing resource allocation, and continuously enhancing product competitiveness. Currently, all product pipelines are progressing smoothly, steadily reaching their expected goals. During the reporting period, Trastuzumab received approval from the China CDE for inclusion in the "Priority Review Drug List," and the company has submitted a new drug marketing application which has been accepted. The product is about to enter the commercialization stage in China. The international multicenter Phase III clinical trial in the field of bile duct cancer is also progressing steadily.